Kara N. Maxwell, MD, PHD
Medical Oncology
Accepting new patients
Sees patients age 18 and up
Rena Rowan Breast Center
Penn Medicine Provider

About me

  • Assistant Professor of Medicine (Hematology-Oncology)
  • Assistant Professor of Medicine in Genetics

Education and training

  • Medical School: NewYork-Presbyterian / Weill Cornell Medical Center
  • Residency: NewYork-Presbyterian/Columbia University Medical Center
  • Fellowship: University of Pennsylvania Health System

What my patients think about me

Average Rating

125 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

December 2025
throughness of the dr in answering my questions
November 2025
she's a great clinician! keeps up with the literature. provides updates to her patients on what is current. knows her patient.
November 2025
just had an overall great experience
November 2025
i have 100% confidence in dr. kara maxwell. she is the best.

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Maxwell is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Corbett RJ, Kaufman RS, McQuaid SW, Vaksman Z, Phul S, Brown MA, Mason JL, Waszak SM, Zhang B, Zhong C, Desai H, Hausler R, Naqvi AS, Chroni A, Geng Z, Gonzalez EM, Zhu Y, Heath AP, Li M; Penn Medicine BioBank; Regeneron Genetics Center; Storm PB, Resnick AC, Maxwell KN, Cole KA, Waanders AJ, Bornhorst M, MacFarland SP, Rokita JL, Diskin SJ Germline pathogenic variation impacts somatic alterations and patient outcomes in pediatric CNS tumors , Nat Commun, 16(1): 2025,10282


Buckley KH, Dungan ME, Dinh K, Kelly GM, Hausler R, Bennett KE, Clay DG, Youngman JE, Majer AD, Beyries KA, Niccum BA, Shaffer SM, Karakasheva TA, Hamilton KE, Kochman ML, Ginsberg GG, Ahmad N, Maxwell KN, Katona BW Gastric epithelium from BRCA1 and BRCA2 carriers harbors increased double-stranded DNA damage and augmented growth , biorxv, 10.01.679809: 2025


Johnatty SE, Tudini E, Parsons MT, Michailidou K, Zanti M, Canson D, Davidson AL, Berger T, Rosti RO, Kratz CP, Kalb R, McReynolds LJ, Giri N, Richardson M, Pesaran T, Surrallés J, Pujol R, Vundinti BR, George M, Maxwell KN, Nathanson K, Domchek S, Fiesco-Roa MÓ, Frias S, Garcia-de-Teresa B, Jongmans M, Lalani S, Maiburg M, Prescott K, Robinson R, Rajagopalan S, Blok LS, Temple SEL, Tucker K, Auerbach AD, Cancio MI, Kennedy JA, MacMillan ML, Tryon R, Wagner JE, Walsh M, Boddicker NJ, Hu C, Weitzel JN, Dingemans AJM, Hadler J, Rotenberg N, Ramadane-Morchadi L, de la Hoya M, James P, Van Overeem Hansen T, Vreeswijk MPG, Walker LC, Sharan SK, Easton DF, Couch F, Smogorzewska A, Nelson A, Ngeow J, Tischkowitz M, Gomez-Garcia E, Spurdle AB. BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotes , Am J Hum Genet, 112(12): 2025,2902-2921


Raychaudhuri R, Garraway IP, Maxwell KN, Rettig M, Desai H, Schoen MW, Schweizer MT, Beltran H, Nelson PS, Montgomery B. Prognostic Significance of RB1 Alterations on Outcomes in Metastatic Prostate Cancer , JCO Precis Oncol, e2500341: 2025


Skuli SJ, Bakayoko A, Kruidenier M, Manning B, Pammer P, Salimov A, Riley O, Brake-Sillá G, Dopkin D, Bowman M, Martinez-Gutierrez LN, Anderson CC, Reisz JA, Buono R, Paul M, Saland E, Liccardo F, DeVine A, Wong S, Xu JP, Nee E, Hausler R, Boettcher S, Sebti SM, Lai C, Maxwell KN, Sarry JE, Fruman DA, D'Alessandro A, Mesaros C, Keith B, Simon MC, Sung PJ, Wertheim G, Skuli N, Bowman RL, Matthews A, Carroll M Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response , Leukemia, 39(9): 2025,2087-2098.


Crawford TB, Nelson T, Karunamuni R, Desai H, Hausler R, Teerlink C, Carter H, Pagadala MS, Alba PR, DuVall SL, Danowski ME, Brunette CA, Ratner D, Garraway IP, Rose BS, Cooney KA, Vassy JL, Hauger RL, Lynch JA, Seibert TM, Maxwell KN Association of HOXB13 G84E with prostate cancer among 592,158 men , J Natl Compr Canc Netw, 23(10): 2025,e257055


Fischer NW, Ong N, Laverty B, Psarianos P, Giovino C, Alon N, Montellier E, Hainaut P, Maxwell KN, Kratz CP, Kafri R, Malkin D TP53 variant clusters stratify phenotypic diversity in germline carriers and reveal an osteosarcoma-prone subgroup , Nat Commun, 16(1): 2025,8546


Crawford TB, Tayeb M, Barrett E, Al-Saleem T, Kondam P, Hausler R, Symecko H, Orr C, Wolfe C, Mann D, Spielman K, Wong G, Haas N, Narayan V, Robinson K, Takvorian S, Wong YN, Sokolova A, Montgomery RB, Menendez C, Kelley MJ, Aiello LB, Garraway IP, Domchek SM, Maxwell KN Pathogenic germline variants in a racially diverse real-world cohort of prostate cancer patients , medrxiv, 2025.08.13.25333614: 2025


Cappadocia J, Maxwell KN, Nathanson KL, Bagley S, Powers J, Halper-Stromberg E, Roth JJ, Domchek S, Shah PD. Exploration of possible association of BRIP1 pathogenic variants with central nervous system cancers in an institutional cohort , J Med Genet, jmg-2025-11076: 2025


Fernandes CJ, Du YK, Naumer A, Kagami LA, Le A, Good M, Duvall M, Powers J, Zelley K, Maese L, MacFarland S, Kohlmann W, Maxwell KN, Katona BW Pancreatic Cancer Risk and Screening Outcomes in Li-Fraumeni Syndrome , Pancreas, 54(7): 2025,e618-e623.


View all publications